Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Posts Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) released its earnings results on Tuesday. The company reported $0.18 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.15 by $0.03, Zacks reports. Shionogi & Co., Ltd. Unsponsored ADR had a return on equity of 13.70% and a net margin of 41.82%.

Shionogi & Co., Ltd. Unsponsored ADR Price Performance

Shares of OTCMKTS:SGIOY traded down $1.50 during trading on Tuesday, reaching $8.67. 520,844 shares of the company’s stock traded hands, compared to its average volume of 101,658. Shionogi & Co., Ltd. Unsponsored ADR has a fifty-two week low of $7.38 and a fifty-two week high of $12.00. The company has a quick ratio of 5.21, a current ratio of 5.84 and a debt-to-equity ratio of 0.01. The firm has a market cap of $14.76 billion, a PE ratio of 11.41, a P/E/G ratio of 0.75 and a beta of 0.10. The company has a 50-day simple moving average of $10.57 and a 200-day simple moving average of $9.77.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. Zacks Research downgraded Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong sell” rating in a research report on Thursday, April 16th. The Goldman Sachs Group raised Shionogi & Co., Ltd. Unsponsored ADR to a “hold” rating in a research report on Wednesday, April 8th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Shionogi & Co., Ltd. Unsponsored ADR presently has an average rating of “Reduce”.

About Shionogi & Co., Ltd. Unsponsored ADR

Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders.

The company’s product portfolio spans both established and innovative therapies.